Curidium Medica plc
Curidium Medica plc is a company in the field of personalised medicine, focused on identifying targeted medicines and companion diagnostics to treat patients more effectively. Curidium’s initial focus on diseases of the central nervous system has resulted in the identification of a blood diagnostic test, PsychINDx, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.
In their recently reported interim results, Curidium reported a loss before tax for the six month period to 30 June of £532,614 (2006: £-120,043). Management reported progress in the period, in establishing Curidium in the growing area of personalised medicine. In 2007, Homomatrix, the Company’s core technology, was fine-tuned, automated and subsequently applied to three different datasets in schizophrenia/bipolar disorder. The outcome was the identification of four highly statistically different subgroups of patients within schizophrenia/bipolar disorder. It is hoped that the identification of these subgroups may offer the potential of better selection of patient treatments as well as the identification of novel drugs targeting one or more of the subgroups.
BUYING SIGNAL: speculative buy
COMPANY NAME: Curidium Medica plc
COMPANY TICKER: CUR.L
COUNTRY: United Kingdom